Turnstone Biologics Reports Encouraging Phase 1 Results

Turnstone Biologics Corp. (TSBX) just unveiled an update.

Turnstone Biologics Corp. has shared promising initial data from its Phase 1 clinical trials for TIDAL-01, sparking investor interest. The details were released in a recent press statement and further elaborated in an updated corporate presentation on their website. This information, while informative, is not considered part of the formal financial filings but is accessible for those tracking the company’s progress.

For detailed information about TSBX stock, go to TipRanks’ Stock Analysis page.